In the News
Leveragen and 92Bio Forge Strategic Alliance to Advance Therapeutics Using Novel Single Domain Antibody Platform
WOBURN, Mass.--Leveragen, Inc., a Boston-based early-stage biotech company developing next-generation genetic models for antibody discovery, announced today that it has entered into a multi-target commercial license agreement with 92Bio, Inc., a biotech firm focused...
Ginkgo Technology Network Launches, Providing an Integrated R&D Experience with Capabilities from Over 25 Inaugural Partners
Leveragen is proud to take part in Ginkgo Technology Network. Read More